18.03.2021 • News

EMA Gives All Clear for AstraZeneca Covid Shot

After a day’s deliberation, the European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19 vaccine is safe and effective and that potential side effects observed across the EU are not too great to run the risk of being infected with the virus.

EMA launched its review following moves by more than 12 EU member states to temporarily halt inoculations with the shot over fears it could lead to very rare cases of blood clots, in combination with thrombocytopenia (low levels of blood platelets).

The medicines agency said it found no batch issues or quality issues with the vaccine, although it was unable to definitively rule out a link with the blood clot incidents. The EMA plans to continue studying possible links between the blood clots and the vaccine and also will update its guidance for the vaccine to explain potential risks.

Some 30 cases of blood clots were reported in people who had received the vaccine originally developed by the University of Oxford in the UK. Some countries halted shots altogether, while others stopped using individual batches of the vaccine.

Before its review, the EMA recommended that EU countries continue vaccinations with the shot as did the World Health Organization. The discussion over the risks associated with the clots helped heat up the cold war between the UK and the EU. Brexit hardliners accused European officials of trying to sabotage the British-made vaccine in retaliation for Britain’s leaving the bloc.

Author: Dede Williams, Freelance Journalist

The European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19...
The European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19 vaccine is safe and effective and that potential side effects observed across the EU are not too great to run the risk of being infected with the virus that is gaining strength across Europe again. (c) AstraZeneca

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

most read